Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.
View Article and Find Full Text PDFAnn Allergy Asthma Immunol
August 2022
J Allergy Clin Immunol Pract
November 2021
Background: Higher asthma burden is more likely to be experienced by Black than White patients. In clinical research, underrepresentation of minority populations is observed.
Objective: To estimate response to omalizumab in Black and White patients in North America with moderate to severe asthma.